Basal Plus GLP1-ra on Glycemic Variability in CKD

NCT05218915 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding a GLP-1 receptor agonist to basal insulin can help manage blood sugar fluctuations in adults with diabetes and kidney disease.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 95 people

Who can join Ages 18–75 · all sexes

Timeline Started 2022-01 · est. completion 2024-10

Where 1 site · Hong Kong

What this study is testing ClinicalTrials.gov NCT05218915 ↗

Description as written by the study sponsor.

To compare GLP-1 RA plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycemic variability (GV) and time in range (TIR) in diabetes patients CKD stage 3-4

Treatments tested

Dulaglutide Drug

Dulaglutide once weekly subcutaneous
Insulin Degludec Drug

Insulin degludec once daily
Continuous glucose monitor Device

Dexcom G6 CGM system

Main thing measured	Glycemic variability
Sponsor	Elaine Chow
Conditions studied	Diabetes Mellitus, Diabetic Kidney Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05218915 ↗